Predict your next investment

Venture Capital
droiaventures.com

See what CB Insights has to offer

Investments

22

Portfolio Exits

2

Funds

1

About DROIA Ventures

DROIA Ventures is a venture investor that focuses exclusively on the development of oncology therapies. DROIA is dedicated to making a difference in the fight against cancer. The firm has adopted a unique investment model to accelerate development in its portfolio companies, the DROIACs.

DROIA Ventures Headquarter Location

Brusselsesteenweg 11

Meise, 1860,

Belgium

+32 2 880 67 30

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest DROIA Ventures News

Vicinitas Therapeutics Launches With $65M

Jul 29, 2022

Vicinitas Therapeutics, a biotechnology company advancing a proprietary targeted protein stabilization platform to develop novel therapeutics in cancer and genetic disorders, today launched with $65 million in Series A financing. The financing was co-led by a16z and Deerfield Management, with participation from Droia Ventures, GV, The Mark Foundation for Cancer Research and the Berkeley Catalyst Fund. Vicinitas Therapeutics is a spin-out company that resulted from the Deubiquitinase Targeting Chimera (DUBTAC) platform, which was developed through an academic-industry research collaboration between the Novartis Institutes for BioMedical Research and researchers at the University of California, Berkeley. Vicinitas Therapeutics is a biotechnology company focused on targeted protein stabilizers known as Deubiquituinase Targeting Chimeras (DUBTACs). The company's mission is to use this proprietary technology to solve critical problems in human health by developing next-generation disease therapies against an entire class of previously inaccessible disease-causing proteins. (c)2011-2020 by Massinvestor, Inc. For contact info, please check out our about page.

DROIA Ventures Investments

22 Investments

DROIA Ventures has made 22 investments. Their latest investment was in Vicinitas Therapeutics as part of their Series A on July 7, 2022.

CBI Logo

DROIA Ventures Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

7/28/2022

Series A

Vicinitas Therapeutics

$65M

Yes

3

1/6/2022

Series A

AmbAgon Theraputics

$85M

No

19

7/12/2021

Series B

Frontier Medicines

$88.5M

No

17

7/9/2021

Series A

Subscribe to see more

$99M

Subscribe to see more

10

5/18/2021

Series C

Subscribe to see more

$99M

Subscribe to see more

10

Date

7/28/2022

1/6/2022

7/12/2021

7/9/2021

5/18/2021

Round

Series A

Series A

Series B

Series A

Series C

Company

Vicinitas Therapeutics

AmbAgon Theraputics

Frontier Medicines

Subscribe to see more

Subscribe to see more

Amount

$65M

$85M

$88.5M

$99M

$99M

New?

Yes

No

No

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

3

19

17

10

10

DROIA Ventures Portfolio Exits

2 Portfolio Exits

DROIA Ventures has 2 portfolio exits. Their latest portfolio exit was Cyteir Therapeutics on June 18, 2021.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

6/18/2021

IPO

$99M

Public

1

3/15/2018

IPO

Subscribe to see more

$99M

Subscribe to see more

10

Date

6/18/2021

3/15/2018

Exit

IPO

IPO

Companies

Subscribe to see more

Valuation

$99M

$99M

Acquirer

Public

Subscribe to see more

Sources

1

10

DROIA Ventures Fund History

1 Fund History

DROIA Ventures has 1 fund, including Droia Ventures Fund III.

Closing Date

Fund

Fund Type

Status

Amount

Sources

5/11/2021

Droia Ventures Fund III

$265M

2

Closing Date

5/11/2021

Fund

Droia Ventures Fund III

Fund Type

Status

Amount

$265M

Sources

2

DROIA Ventures Team

2 Team Members

DROIA Ventures has 2 team members, including current Managing Partner, Janwillem Naesens.

Name

Work History

Title

Status

Janwillem Naesens

Waterland Private Equity Investments, and McKinsey & Company

Managing Partner

Current

Jonas Dhaenens

Investment Partner

Current

Name

Janwillem Naesens

Jonas Dhaenens

Work History

Waterland Private Equity Investments, and McKinsey & Company

Title

Managing Partner

Investment Partner

Status

Current

Current

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.